Sutro Biopharma, Inc.

STRO • Biotechnology

$20.07

▼ -0.47 (-2.29%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$332.59M

Growth

-40.8%

Cash Flow

0/5

Trend

Negative

Evidence

Healthy liquidity · 2.01Negative growth trendWeak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 14, 2026, 12:19 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$20.07

Change-2.29%

Shares Out16.57M

Market Cap$332.59M

Enterprise Value$179.03M

52W Range7.15 - 43.85

Beta1.52

P/E-1.84

P/S7.28

P/B-3.22

P/FCF-2.28

EV/Sales3.92

Price$20.07

Change-2.29%

Shares Out16.57M

Market Cap$332.59M

Enterprise Value$179.03M

52W Range7.15 - 43.85

Beta1.52

P/E-1.84

P/S7.28

P/B-3.22

P/FCF-2.28

EV/Sales3.92

EV/EBITDA-1.32

EV/FCF-1.23

Earnings Yield-54.31%

FCF Yield-43.78%

Dividend Yield0.00%

Gross Margin92.85%

Oper. Margin-102.41%

Profit Margin-186.45%

Debt/Eq-0.12

Current Ratio2.01

Quick Ratio2.01

Revenue 5Y-40.82%

Target$51.00

Target Upside154.11%

Target Median$50.00

Target Range43.00 - 60.00

Volume549.49K

Avg Volume315.10K

EPS Surprise-0.62

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

70/100

Growth Potential

Revenue and expansion

20/100

Price Attractiveness

Cheap or expensive today

95/100

Why this score▼

Healthy liquidity · 2.01Negative growth trendWeak profitability

Analyst view

Analyst sentiment and price target

STRO

Analyst sentiment

Based on 20 analyst votes · 2026-09-05

93/100

Bullish

Hold

Bearish

Price Target

2026-08-14

Low

$43.00

Mean

$51.00

Median

$50.00

High

$60.00

Company Overview

IPO: 9/27/2018

Industry: Biotechnology

P/B i: -3.22

Debt / Equity i: -0.12

Operating Margin: -102.41%

Net Margin: -186.45%

ROE i: -

ROIC: -

Financial Health

Score14 / 20

Debt / Equity: -0.12

Current Ratio: 2.01

Quick Ratio: 2.01

Status: Good

Insider Transactions

Recent executive and insider activity

MATSUI CONNIE

Transaction: 06/05/2026

BUY

Change

+10,000

Price

$26.09

Filing

06/09/2026

Type

BUY

Dybbs Michael

Transaction: 06/05/2026

BUY

Change

+10,000

Price

$26.09

Filing

06/09/2026

Type

BUY

Hunter Heidi

Transaction: 06/05/2026

BUY

Change

+10,000

Price

$26.09

Filing

06/09/2026

Type

BUY

Insider	Type	Change	Price	Transaction	Filing
MATSUI CONNIE	BUY	+10,000	$26.09	06/05/2026	06/09/2026
Dybbs Michael	BUY	+10,000	$26.09	06/05/2026	06/09/2026
Hunter Heidi	BUY	+10,000	$26.09	06/05/2026	06/09/2026
Jagpal Sukhi	BUY	+10,000	$26.09	06/05/2026	06/09/2026
Lobacki Joseph M	BUY	+10,000	$26.09	06/05/2026	06/09/2026
PANEK JAMES P	BUY	+10,000	$26.09	06/05/2026	06/09/2026
Petree Daniel H	BUY	+10,000	$26.09	06/05/2026	06/09/2026
Wigginton Jon Marc	BUY	+10,000	$26.09	06/05/2026	06/09/2026
Chow Gregory K.	BUY	+2,500	Not reported	06/02/2026	06/02/2026
Chow Gregory K.	SELL	-2,500	Not reported	06/02/2026	06/02/2026
Chung Jane	SELL	-788	Not reported	03/04/2026	03/06/2026
Chung Jane	SELL	-282	$21.31	03/04/2026	03/06/2026
Pauling David	SELL	-675	Not reported	03/04/2026	03/06/2026
Pauling David	SELL	-277	$21.31	03/04/2026	03/06/2026
Chung Jane	SELL	-2,779	$20.55	03/02/2026	03/03/2026
Chung Jane	SELL	-7,750	Not reported	03/02/2026	03/03/2026
Chung Jane	BUY	+175,000	$20.55	03/02/2026	03/03/2026
Chow Gregory K.	BUY	+5,000	Not reported	03/02/2026	03/03/2026
Chow Gregory K.	BUY	+40,000	$20.55	03/02/2026	03/03/2026
Gerber Hans-Peter	BUY	+5,000	Not reported	03/02/2026	03/03/2026

About the Company

Sutro Biopharma, Inc.

Sutro Biopharma, Inc. is a clinical-stage biotechnology company focused on the discovery, development, and manufacturing of innovative therapeutic products. Its primary objective is to create protein-based treatments for challenging conditions like cancer and autoimmune disorders. The company achieves this through its proprietary XpressCF+ platform, a unique technology that integrates cell-free protein synthesis with precise, site-specific drug conjugation. Currently, Sutro's pipeline features two lead antibody-drug conjugate (ADC) candidates, both undergoing Phase 1 clinical evaluation. STRO-001 targets the CD74 protein, designed for individuals with multiple myeloma and non-Hodgkin lymphoma. The second candidate, STRO-002, is engineered to bind to folate receptor-alpha, intended for the treatment of ovarian and endometrial cancers. Strategic alliances are also a key part of its strategy, including collaborations and licensing agreements. A partnership with Merck aims to advance research programs involving cytokine derivatives for both oncological and autoimmune applications. Additionally, an agreement with Celgene Corporation focuses on identifying and developing bispecific antibodies and/or ADCs specifically within the immuno-oncology domain. Founded in 2003, the company initially operated under the name Fundamental Applied Biology, Inc. Its corporate headquarters are located in South San Francisco, California.

Source - link

Peers

ADVM ARTV CNTB DTIL GUTS IFRX KLRS MGX PLRX STTK

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Cardio Diagnostics (NASDAQ:CDIO) & Sutro Biopharma (NASDAQ:STRO) Head-To-Head Analysis

Sutro Biopharma (NASDAQ: STRO - Get Free Report) and Cardio Diagnostics (NASDAQ: CDIO - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, institutional ownership, valuation, risk and profitability. Profitability This table compares Sutro Biopharma and

Defense World

Why is Sutro Biopharma Stock Falling On Wednesday?

Sutro Biopharma, Inc. (NASDAQ:STRO) shares are trading lower on Wednesday as the company faces challenges following its recent update on the STRO-004 Phase 1 study.

Benzinga

Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study

– Encouraging early clinical activity i ncluding confirmed and ongoing unconfirmed partial responses with favorable tolerability, and pharmacokinetics (PK) observed in ongoing STRO-004 Phase 1 study – – Strong execution of STRO-004 STRIVE-01 study with rapid enrollment of initial dose escalation cohorts within 7 months; dose optimization ongoing between 4-5 mg/kg – – STRO-006, next-generation integrin 6 (ITGB6)-targeting ADC, is on track to enter the clinic in the third quarter of 2026 – – Second dual-payload iADC program from Sutro's platform under Astellas collaboration expected to enter the clinic in the second half of 2026 – – Strong balance sheet with $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, expected to support operations into at least the second quarter of 2028 – SOUTH SAN FRANCISCO, Calif., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the second quarter ended June 30, 2026 and recent business highlights.

GlobeNewsWire

Here Are Friday’s Top Wall Street Analyst Research Calls: Baker Hughes, Etsy, HubSpot, Instacart, JetBlue, Roku, SpaceX, Tower Semiconductor, Trade Desk, and More

Wall Street analysts reshuffled their ratings on Friday with some bold calls that could move money fast, including a dramatic target cut on Trade Desk and a fresh Buy on SpaceX as markets brace for next week's inflation data.

247 Wallst

Affinity Asset Advisors LLC Grows Stock Holdings in Sutro Biopharma, Inc. $STRO

Affinity Asset Advisors LLC grew its holdings in shares of Sutro Biopharma, Inc. (NASDAQ: STRO) by 42.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,069,519 shares of the company's stock after purchasing an additional 321,137 shares during the

Defense World

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-14	-2.32	-2.94	-0.62
2026-03-23	-8.16266	-5.29	2.87266
2025-11-06	-4.2	-6.7	-2.5
2025-08-07	-0.39	-0.14	0.25
2025-05-08	-0.63	-0.91	-0.28
2025-03-13	-0.86	-0.89	-0.03
2024-11-13	-0.74	-0.59	0.15
2024-08-13	-0.76	-0.59	0.17
2024-05-13	-0.92	-0.95	-0.03
2024-03-25	-0.82	0.42	1.24
2023-11-13	-0.76	-0.81	-0.05
2023-08-10	-0.73	-0.64	0.09